Gene therapy restores vision in a canine model of childhood blindness
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [64]
Citations
Cites
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Identification of the gene responsible for Best macular dystrophy
Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., et al. (1998) · Nature Genetics · doi:10.1038/915 · Cited by 689
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationBiochemistry of visual pigment regeneration: the Friedenwald lecture.
Saari, J. C. (2000) · PubMed · Cited by 270
Simon, A., Hellman, U., Wernstedt, C., & Eriksson, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1107 · Cited by 254
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252
Self-citationAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Self-citation
Cited by
Items 301–400 of 1,000
Retinitis Pigmentosa and Allied Diseases
Berson, E. L. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-0016-7.50180-6 · Cited by 73
Williams, D. L. (2008) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2007.10.006 · Cited by 72
Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence
Gao, J., Hussain, R. M., & Weng, C. Y. (2020) · Clinical ophthalmology · doi:10.2147/opth.s231804 · Cited by 86
Majowicz, A., Maczuga, P., Kwikkers, K. L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S. J., Konstantinova, P., & Ferreira, V. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2712 · Cited by 71
Ocular Delivery of Compacted DNA-Nanoparticles Does Not Elicit Toxicity in the Mouse Retina
Ding, X.-Q., Quiambao, A. B., Fitzgerald, J. B., Cooper, M. J., Conley, S. M., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007410 · Cited by 71
“For example, restoration of retinal function by viral-mediated gene delivery was documented in canine (RPE65 dog) [3,4] and”
BackgroundGene therapy for inherited retinal disease: Long-term durability of effect
Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023) · Ophthalmic Research · doi:10.1159/000526317 · Cited by 70
“…have been developed and tested in various animal and disease models by multiple research groups (Table 1), including safety and efficacy studies in a large animal model of childhood blindness (the RPE65 −/− dog) [24, 25], and safety of an alternative ocular rAAV2-RPE65 in nonhuman primates [26].”
BackgroundOcular gene therapy: current progress and future prospects
Colella, P., Cotugno, G., & Auricchio, A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.003 · Cited by 78
Grüter, O., Kostic, C., Crippa, S. V., Perez, M.-T. R., Zografos, L., Schorderet, D. F., Munier, F. L., & Arsenijévic, Y. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302485 · Cited by 78
Zhu, L., Jang, G.-F., Jastrzebska, B., Filipek, S., Pearce-Kelling, S. E., Aguirre, G. D., Stenkamp, R. E., Acland, G. M., & Palczewski, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408472200 · Cited by 70
Self-citationAmeri, H. (2018) · Journal of Current Ophthalmology · doi:10.1016/j.joco.2018.01.006 · Cited by 70
“In 2001, briard dogs with RPE65 mutation were successfully treated by gene therapy delivered through subretinal injection; the same study indicated that intravitreal delivery was not effective.(4) The positive results of a phase 1 human clinical trial in 2009 followed by a successful phase 3 trial in 2017 lead to the…”
BackgroundTechnical brief: subretinal injection and electroporation into adult mouse eyes.
Johnson, C. J., Berglin, L., Chrenek, M. A., Redmond, T. M., Boatright, J. H., & Nickerson, J. M. (2008) · PubMed Central · Cited by 69
Therapeutic Challenges to Retinitis Pigmentosa: From Neuroprotection to Gene Therapy
N. Sahni, J., Angi, M., Irigoyen, C., Angi, M., Semeraro, F., R. Romano, M., Parmeggiani, F., & Parmeggiani, F. (2011) · Current Genomics · doi:10.2174/138920211795860062 · Cited by 69
“Preliminary trials involving surgical delivery of recombinant AAV carrying wild type rpe65 into the subretinal space of the Briard dog, a natural occurring model with mutation in the RPE65 gene, demonstrated dramatic improvements in the light sensitivity of rods and cones [31-35].”
BackgroundInherited neurodegenerative diseases: the one-hit model of neurodegeneration
Clarke, G. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.20.2269 · Cited by 69
Defective Trafficking of Rhodopsin and Its Role in Retinal Degenerations
Hollingsworth, T., & Gross, A. K. (2012) · International review of cytology · doi:10.1016/b978-0-12-394304-0.00006-3 · Cited by 78
Li, S., Datta, S., Brabbit, E., Love, Z., Woytowicz, V., Flattery, K., Capri, J., Yao, K., Wu, S., Imboden, M., et al. (2021) · Gene Therapy · doi:10.1038/s41434-020-0134-z · Cited by 68
“The most widely accepted success of adeno-associated virus (AAV) vector-mediated ocular gene replacement is for treatment of Leber ’ s congenital amaurosis 2 (LCA2), a rare retinal disease due to mutations in the RPE65 gene [8, 9].”
BackgroundRetinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 78
“The development of the treatment started in LCA animal models [96–99] and further promising human clinical trials followed [100–103].”
BackgroundAssessment of Adeno-Associated Virus Serotype Tropism in Human Retinal Explants
Wiley, L. A., Burnight, E. R., Kaalberg, E. E., Jiao, C., Riker, M. J., Halder, J. A., Luse, M. A., Han, I. C., Russell, S. R., Sohn, E. H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.179 · Cited by 68
“More than 15 years ago, researchers took advantage of this accessibility and the nonpathogenicity of adeno-associated virus (AAV) to deliver AAVs to the sub-retinal space and demonstrated that AAV-mediated gene replacement therapy could restore vision in a canine model of RPE65-associated LCA.2 The efficacy demonstrat…”
BackgroundLeber Congenital Amaurosis (LCA): Potential for Improvement of Vision
Cideciyan, A. V., & Jacobson, S. G. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-26672 · Cited by 74
Self-citationResults at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy
Pennesi, M. E., Weleber, R. G., Yang, P., Whitebirch, C., Thean, B., Flotte, T. R., Humphries, M., Chegarnov, E., Beasley, K. N., Stout, J. T., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.014 · Cited by 68
Cashman, S. M., Sadowski, S. L., Morris, D. J., Frederick, J., & Kumar-Singh, R. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0806 · Cited by 68
Long-term Structural Outcomes of Late-stage RPE65 Gene Therapy
Gardiner, K. L., Cideciyan, A. V., Swider, M., Dufour, V. L., Sumaroka, A., Komáromy, A. M., Hauswirth, W. W., Iwabe, S., Jacobson, S. G., Beltran, W. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.013 · Cited by 67
Self-citationGene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art
Amato, A., Arrigo, A., Aragona, E., Manitto, M. P., Saladino, A., Bandello, F., & Battaglia Parodi, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.750586 · Cited by 67
“Proof of principle for retinal gene therapy came from the pioneering studies conducted in the early 2000’s on a peculiar canine model (127, 128).”
BackgroundProsthetic interfaces with the visual system: biological issues
Cohen, E. D. (2007) · Journal of Neural Engineering · doi:10.1088/1741-2560/4/2/r02 · Cited by 67
“While it is likely that genetic vectors or stem cell technology may ultimately repair some forms of RP (Acland et al 2001), the sheer number of mutations involved precludes simple therapies and may require intact rod precursors (MacLaren et al 2006).”
BackgroundOcular gene therapy: a review of nonviral strategies.
Andrieu‐Soler, C., Bejjani, R. A., de Bizemont, T., Normand, N., BenEzra, D., & Béhar‐Cohen, F. (2006) · PubMed · Cited by 77
Optimized Production of High-Titer Recombinant Adeno-Associated Virus in Roller Bottles
Liu, Y.-L., Wagner, K., Robinson, N., Sabatino, D., Margaritis, P., Xiao, W., & Herzog, R. W. (2003) · BioTechniques · doi:10.2144/03341dd07 · Cited by 67
Functional MRI of Congenital Hyposmia: Brain Activation to Odors and Imagination of Odors and Tastes
Henkin, R. I., & Levy, L. M. (2002) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-200201000-00008 · Cited by 75
“This hypothesis has recently been explored in congenitally blind dogs in which the RPE65 gene related to congenital amaurosis was inserted in vivo with correction of some aspects of blindness (317).”
BackgroundLeber's Hereditary Optic Neuropathy-Gene Therapy: From Benchtop to Bedside
Koilkonda, R. D., & Guy, J. (2011) · Journal of Ophthalmology · doi:10.1155/2011/179412 · Cited by 66
“Thus, the AAV vector has a proven track record in human clinical trials [98–101].”
BackgroundRPE65 gene therapy slows cone loss in Rpe65-deficient dogs
Mowat, F. M., Breuwer, A. R., Bartoe, J. T., Annear, M. J., Zhang, Z., Smith, A. J., Bainbridge, J. W., Petersen‐Jones, S. M., & Ali, R. R. (2012) · Gene Therapy · doi:10.1038/gt.2012.63 · Cited by 70
Stem cells for investigation and treatment of inherited retinal disease
Tucker, B. A., Mullins, R. F., & Stone, E. M. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu124 · Cited by 74
Gene and cell‐based therapies for inherited retinal disorders: An update
Sengillo, J. D., Justus, S., Tsai, Y., Cabral, T., & Tsang, S. H. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31534 · Cited by 65
“An AAV-mediated therapeutic gene delivery was used in a naturally occurring canine model for LCA2 (RPE65 / ) in 2001, which led to the long-term restoration of vision in treated dogs [Acland et al., 2001].”
Li, X., Li, W., Dai, X., Kong, F., Zheng, Q., Zhou, X., Lü, F., Chang, B., Rohrer, B., Hauswirth, W. W., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6138 · Cited by 64
Self-citationRetinoid cycle in the vertebrate retina: experimental approaches and mechanisms of isomerization
Kuksa, V., Imanishi, Y., Batten, M., Palczewski, K., & Moise, A. R. (2003) · Vision Research · doi:10.1016/s0042-6989(03)00482-6 · Cited by 64
DeMarco, P. J., Yarbrough, G. L., Yee, C. W., McLean, G. Y., Sagdullaev, B. T., Ball, S. L., & McCall, M. A. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0811 · Cited by 63
Touchard, E., Berdugo, M., Bigey, P., El Sanharawi, M., Savoldelli, M., Naud, M.-C., Jeanny, J.-C., & Behar-Cohen, F. (2012) · Molecular Therapy · doi:10.1038/mt.2011.304 · Cited by 63
Roman, A. J., Cideciyan, A. V., Wu, V., Garafalo, A. V., & Jacobson, S. G. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101000 · Cited by 63
Self-citationJacobson, S. G., Cideciyan, A. V., Alemán, T. S., Sumaroka, A., Román, A. J., Świder, M., Schwartz, S., Banin, E., & Stone, E. M. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6127 · Cited by 70
Self-citationInner retinal abnormalities in a mouse model of Leber's congenital amaurosis
Pignatelli, V., Cepko, C. L., & Strettoi, E. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.11019 · Cited by 67
“Therapies under development include the transplantation of photoreceptor cells (Lund et al., 2001), gene therapy (Acland et al., 2001), and epiretinal and subretinal implants of electronic prostheses (Humayun and De Juan, 1998).”
BackgroundA review of in vivo animal studies in retinal prosthesis research
Bertschinger, D. R., Beknazar, E., Simonutti, M., Safran, A. B., Sahel, J., Rosolen, S. G., Picaud, S. A., & Salzmann, J. (2008) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0891-7 · Cited by 68
“These dogs were famously used in the first effective viral transfection gene therapy trial for blindness [1].”
BackgroundUnexpected CEP290 mRNA Splicing in a Humanized Knock-In Mouse Model for Leber Congenital Amaurosis
Garanto, A., van Beersum, S. E. C., Peters, T. A., Roepman, R., Cremers, F. P. M., & Collin, R. W. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079369 · Cited by 62
“gene augmentation therapy in dogs [40].”
Sanders, N. N., Peeters, L., Lentacker, I., Demeester, J., & Smedt, S. C. D. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.004 · Cited by 63
Safety of adeno-associated virus gene therapy vectors: a current evaluation
Monahan, P. E., Jooss, K., & Sands, M. S. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.1.79 · Cited by 62
“Large animal models of singleadministration AAV2 treatment to the muscle [42,43] and liver [44] have demonstrated persistent expression for > 3 years; expression in primate lung [45] and canine retina [46] have persisted 6 and 4 months, respectively.”
BackgroundÖztürk, B. E., Johnson, M. E., Kleyman, M., Turunç, S., He, J., Jabalameli, S., Xi, Z., Visel, M., Dufour, V., Iwabe, S., et al. (2021) · eLife · doi:10.7554/elife.64175 · Cited by 66
Self-citationGuziewicz, K. E., Zangerl, B., Komáromy, A. M., Iwabe, S., Chiodo, V. A., Boye, S. L., Hauswirth, W. W., Beltran, W. A., & Aguirre, G. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075666 · Cited by 61
“assessed [19,23] and successfully translated to the human subjects”
BackgroundSelf-citationThe slow wave component of retinal activity inrd/rdmice recorded with a multi-electrode array
Ye, J. H., & Goo, Y. S. (2007) · Physiological Measurement · doi:10.1088/0967-3334/28/9/009 · Cited by 62
Mutation Discovered in a Feline Model of Human Congenital Retinal Blinding Disease
Menotti-Raymond, M. A., Deckman, K. H., David, V. A., Myrkalo, J., O’Brien, S. J., & Narfström, K. L. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4261 · Cited by 65
Downs, L. M., Wallin‐Håkanson, B., Boursnell, M. E. G., Marklund, S. L., Hedhammar, Å. A., Truvé, K., Hübinette, L., Lindblad‐Toh, K., Bergström, T. F., & Mellersh, C. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021452 · Cited by 62
“Further to this, canine models for human eye diseases have proved invaluable in gene-therapy studies, most notably the canine model of Leber congenital amaurosis associated with RPE65 [21,22].”
BackgroundNovel approaches for retinal drug delivery
Kurz, D. E., & Ciulla, T. A. (2002) · Ophthalmology Clinics of North America · doi:10.1016/s0896-1549(02)00034-2 · Cited by 61
“Recently, adeno-associated virus was used to transfer the wild-type RPE65 gene to a dog model of Leber’s congenital amaurosis and restore vision [65].”
MethodAssessment of Structure and Function Over a 3-year Period after Gene Transfer in RPE65−/− dogs
Narfström, K. L., Vaegan, Katz, M. L., Bragadóttir, R., Rakoczy, E. P., & Seeliger, M. W. (2005) · Documenta Ophthalmologica · doi:10.1007/s10633-005-3159-0 · Cited by 67
“On-going studies by another research group applying gene transfer in a different strain of RPE65 null mutation dogs [21] have found no change in ERG parameters and visual function Figure 4.”
BackgroundMechanisms of blindness: Animal models provide insight into distinct CRX ‐associated retinopathies
Tran, N. M., & Chen, S. (2014) · Developmental Dynamics · doi:10.1002/dvdy.24151 · Cited by 64
“These approaches have successfully been used to improve retinal function in animal models of retinal dystrophies (Acland et al., 2001; Bennicelli et al., 2008; Boye et al., 2010; Jiang et al., 2011; Mancuso et al., 2009; O’Reilly et al., 2007; Tam et al., 2008), as well as in human safety trials…”
MethodGilger, B. C., Reeves, K., & Salmon, J. H. (2005) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2005.00401.x · Cited by 60
Tam, L. C. S., Kiang, A., Kennan, A., Kenna, P. F., Chadderton, N., Ader, M., Palfi, A., Aherne, A., Ayuso, C., Campbell, M., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn107 · Cited by 64
Chow, A. Y., Bittner, A. K., & Pardue, M. T. (2010) · PubMed · Cited by 61
Leber's congenital amaurosis: an update
Fazzi, E. M., Signorini, S. G., Scelsa, B., Bova, S. M., & Lanzi, G. (2003) · European Journal of Paediatric Neurology · doi:10.1016/s1090-3798(02)00135-6 · Cited by 60
Yzer, S., van den Born, L. I., Schuil, J., Kroes, H. Y., van Genderen, M. M., Boonstra, F. N., van den Helm, B., Brunner, H. G., Koenekoop, R. K., & Cremers, F. P. M. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.9.709 · Cited by 60
Ciulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1740676 · Cited by 59
Dog Models for Blinding Inherited Retinal Dystrophies
Petersen-Jones, S. M., & Komáromy, A. M. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.155 · Cited by 59
“AAV vectors carrying the Rpe65 cDNA were introduced by subretinal injection and shown to transduce the RPE restoring the visual cycle and resulting in a remarkable improvement in retinal function as assessed by the electroretinogram (ERG) and also in vision as assessed by obstacle course vision testing.(16) This and f…”
BackgroundMethodRebuilding the Missing Part—A Review on Photoreceptor Transplantation
Santos‐Ferreira, T., Borsch, O., & Ader, M. (2017) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2016.00105 · Cited by 68
“, 2012), gene therapy (Acland et al., 2001), antibody therapy (Lazic andGabric, 2007), optogenetics (Busskamp et al.”
BackgroundRyals, R. C., Andrews, M. D., Datta, S., Coyner, A. S., Fischer, C. M., Wen, Y., Pennesi, M. E., & McGill, T. J. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20363 · Cited by 59
Folliot, S., Briot, D., Conrath, H., Provost, N., Cherel, Y., Moullier, P., & Rolling, F. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.367 · Cited by 59
“The restoration of vision in RPE65 dogs [10] and the morphological”
BackgroundMandal, M. N. A., Heckenlively, J. R., Burch, T., Chen, L., Vasireddy, V., Koenekoop, R. K., Sieving, P. A., & Ayyagari, R. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0007 · Cited by 59
“Results of studies of treatments for two different forms of early-onset retinal degeneration have been reported to be successful in animal models, and one can anticipate that some of these treatments may become available to patients in the future.(11,12) However, most of these treatments are specific to patients with…”
BackgroundStable RAAV-Mediated Transduction of Rod and Cone Photoreceptors in the Canine Retina
Bainbridge, J. W. B., Mistry, A., Schlichtenbrede, F. C., Smith, A., Broderick, C., De Alwis, M., Georgiadis, A., Taylor, P. M., Squires, M., Sethi, C., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301990 · Cited by 58
Gene supplementation therapy for recessive forms of inherited retinal dystrophies
Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2011) · Gene Therapy · doi:10.1038/gt.2011.161 · Cited by 66
Lorenz, B., Strohmayr, E., Zahn, S., Friedburg, C., Kramer, M., Preising, M. N., & Stieger, K. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9974 · Cited by 65
Animal models and different therapies for treatment of retinitis pigmentosa.
Rivas, M. A., & Vecino, E. (2009) · PubMed · doi:10.14670/hh-24.1295 · Cited by 76
“Canine pedigrees have enormous genetic mapping potential, especially when well-characterized canine models are used for the analysis and treatment of corresponding human disorders (Aguirre and Rubin, 1975; Acland et al., 2001; Zangerl et al., 2006).”
BackgroundRamlogan‐Steel, C. A., Murali, A., Andrzejewski, S., Dhungel, B., Steel, J. C., & Layton, C. J. (2019) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.13416 · Cited by 57
Finding and interpreting genetic variations that are important to ophthalmologists.
Stone, E. M. (2003) · Europe PMC (PubMed Central) · Cited by 65
Shi, W., van den Hurk, J. A. J. M., Alamo-Bethencourt, V., Mayer, W., Winkens, H. J., Ropers, H., Cremers, F. P. M., & Fundele, R. H. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.04.016 · Cited by 63
Inhaled drug delivery for the targeted treatment of asthma
Boboltz, A., Kumar, S., & Duncan, G. A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114858 · Cited by 63
Layer‐specific anatomical, physiological and functional MRI of the retina
Duong, T. Q., Pardue, M. T., Thulé, P. M., Olson, D. E., Cheng, H., Nair, G., Li, Y., Kim, M., Zhang, X., & Shen, Q. (2008) · NMR in Biomedicine · doi:10.1002/nbm.1311 · Cited by 60
“Evaluation of emerging treatments intended to slow or reverse retinal degeneration, including vitamin A supplementation, intravitreal administration of growth factors (102) and neuroprotective drugs (103), gene therapy (104), and prosthetics (105) would benefit from in vivomonitoring of”
Muraoka, Y., Ikeda, H. O., Nakano, N., Hangai, M., Toda, Y., Okamoto‐Furuta, K., Kohda, H., Kondo, M., Terasaki, H., Kakizuka, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036135 · Cited by 56
“Additionally, in mid-sized animals like rabbits, surgical treatments such as subretinal injection of cells for regenerative therapy [15,16], vectors for gene therapy [17], and implantation of intraocular devices [18,19] are easily performed.”
BackgroundHuman erythropoietin gene therapy for patients with chronic renal failure
Lippin, Y. (2005) · Blood · doi:10.1182/blood-2004-11-4174 · Cited by 57
Chan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
Hohman, T. C. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_91 · Cited by 56
Cellular and Molecular Mechanisms of Pathogenesis Underlying Inherited Retinal Dystrophies
Manley, A., Meshkat, B. I., Jablonski, M. M., & Hollingsworth, T. (2023) · Biomolecules · doi:10.3390/biom13020271 · Cited by 63
Palfi, A., Millington-Ward, S., Chadderton, N., O'Reilly, M., Goldmann, T., Humphries, M. M., Li, T., Wolfrum, U., Humphries, P., Kenna, P. F., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.119 · Cited by 56
“For example, AAV2 = 2-mediated delivery of the RPE-65 gene to Briard dogs presenting with RPE-65 -linked Leber congenital amaurosis (LCA) has been shown to restore vision (Acland et al ., 2001).”
Retinal Prosthetics, Optogenetics, and Chemical Photoswitches
Marc, R., Pfeiffer, R., & Jones, B. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5001233 · Cited by 55
Dyka, F. M., Molday, L. L., Chiodo, V. A., Molday, R. S., & Hauswirth, W. W. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.132 · Cited by 56
Self-citationClinicopathologic effects of mutant GUCY2D in Leber congenital amaurosis
Milam, A. H., Barakat, M., Gupta, N., Rose, L., Alemán, T. S., Pianta, M. J., Cideciyan, A. V., Sheffield, V. C., Stone, E. M., & Jacobson, S. G. (2003) · Ophthalmology · doi:10.1016/s0161-6420(02)01757-8 · Cited by 60
Self-citationLeber congenital amaurosis: a genetic paradigm
Allikmets, R. L. (2004) · Ophthalmic Genetics · doi:10.1080/13816810490514261 · Cited by 59
Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa
Wert, K. J., Davis, R. J., Sancho-Pelluz, J., Nishina, P. M., & Tsang, S. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds466 · Cited by 55
Zhang, W., Kim, S. M., Wang, W., Cai, C., Feng, Y., Kong, W., & Lin, X. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00221 · Cited by 63
Duan, D., Yue, Y., & Engelhardt, J. F. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4751-4759.2003 · Cited by 55
“The development of adeno-associated virus (AAV)-based gene transfer techniques has proven to be an extremely powerful tool for treating many genetic diseases (1, 12).”
BackgroundZangerl, B., Wickström, K., Slavik, J., Lindauer, S. J., Ahonen, S., Schelling, C., Lohi, H., Guziewicz, K. E., & Aguirre, G. K. (2010) · PubMed Central · Cited by 54
Self-citationRetinal degeneration and RPE transplantation in Rpe65(-/-) mice.
Gouras, P., Kong, J., & Tsang, S. H. (2002) · PubMed · Cited by 55
Electrically Assisted Ocular Gene Therapy
Bejjani, R. A., Andrieu‐Soler, C., Bloquel, C., Berdugo, M., BenEzra, D., & Béhar‐Cohen, F. (2007) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2006.12.005 · Cited by 54
The Future Looks Brighter After 25 Years of Retinal Gene Therapy
Auricchio, A., Smith, A. J., & Ali, R. R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.164 · Cited by 52
“15 In 2005, Hurwitz et al . treated retinoblastoma in children using an intraocular injection of an adenoviral vector carrying a suicide gene.”
Dog as a model in studies on human hereditary diseases and their gene therapy
Switonski, M. (2014) · Reproductive Biology · doi:10.1016/j.repbio.2013.12.007 · Cited by 56
Fradot, M., Busskamp, V., Forster, V., Cronin, T., Léveillard, T., Bennett, J., Sahel, J.-A., Roska, B., & Picaud, S. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.157 · Cited by 51
“Efficacy was demonstrated in transgenic and natural murine models for LCA2 (Dejneka et al ., 2004; Lai et al ., 2004; Pang et al ., 2006), as well as in a natural occurring canine model of the disease, the Briard dog (Acland et al ., 2001; Le Meur et al ., 2007).”
Self-citationGearhart, P. M. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.210 · Cited by 52
“The lack of ERG at this intensity is similar to that reported by others.(5) Vision testing correlated with the recovery of darkadapted ERG responses.”
ResultA Large Animal Model for CNGB1 Autosomal Recessive Retinitis Pigmentosa
Winkler, P. A., Ekenstedt, K. J., Occelli, L. M., Frattaroli, A. V., Bartoe, J. T., Venta, P. J., & Petersen‐Jones, S. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072229 · Cited by 54
“For example, dogs with a mutation in RPE65 as a model for Leber congenital amaurosis type II were crucial for preclinical proof-of-concept gene therapy trials [19] which led to phase 1/2 human clinical trials [20,21,22].”
BackgroundMethodAgeing of the retinal pigment epithelium: implications for transplantation
Boulton, M. E., Rôżanowska, M., & Wess, T. J. (2003) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-003-0812-8 · Cited by 52
Sun, W., Gerth‐Kahlert, C., Maeda, A., Lodowski, D. T., Kraak, L. V. D., Saperstein, D. A., Héon, E., & Palczewski, K. (2007) · Vision Research · doi:10.1016/j.visres.2007.04.005 · Cited by 57
Gene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?
Wang, J.-H., Ling, D. L., Tu, L., van Wijngaarden, P., Dusting, G. J., & Liu, G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.01.003 · Cited by 59
“using gene therapy were reported in a canine model of LCA2 (Acland et al., 2001).”
InfluentialPrenatal human ocular degeneration occurs in Leber's congenital amaurosis (LCA2)
Porto, F. B. O., Perrault, I., Hicks, D., Rozet, J., Hanoteau, N., Hanein, S., Kaplan, J., & Alain Sahel, J. (2002) · The Journal of Gene Medicine · doi:10.1002/jgm.278 · Cited by 52
“Such trials have raised hopes that similar approaches could rescue visual function in LCA2 patients [14,22].”
BackgroundCurrent Concepts in the Treatment of Retinitis Pigmentosa
Musarella, M. A., & MacDonald, I. M. (2010) · Journal of Ophthalmology · doi:10.1155/2011/753547 · Cited by 60
“The authors also wish to thank the Foundation Fighting Blindness USA and Canada for providing funding to seek current therapies.”
BackgroundInfluentialGrozdanić, S. D., Matic, M., Sakaguchi, D. S., & Kardon, R. H. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0249 · Cited by 61
Natural models for retinitis pigmentosa: progressive retinal atrophy in dog breeds
Bunel, M., Chaudieu, G., Hamel, C., Lagoutte, L., Manès, G., Botherel, N., Brabet, P., Pilorge, P., André, C., & Quignon, P. (2019) · Human Genetics · doi:10.1007/s00439-019-01999-6 · Cited by 55
Mechanisms of AAV transduction in glaucoma‐associated human trabecular meshwork cells
Borrás, T., Xue, W., Choi, V. W., Bartlett, J. S., Li, G., Samulski, R. J., & Chisolm, S. S. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.886 · Cited by 51
“Adeno-associated viruses type 2 (AAV2) have been, on the other hand, the vectors of choice for other diseases of the eye, especially those involving retinal degeneration [11].”
BackgroundHigh, K. A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01460.x · Cited by 51
Gene Transfer to the Nonhuman Primate Retina with Recombinant Feline Immunodeficiency Virus Vectors
Lotery, A. J., Derksen, T. A., Russell, S. R., Mullins, R. F., Sauter, S., Affatigato, L. M., Stone, E. M., & Davidson, B. L. (2002) · Human Gene Therapy · doi:10.1089/104303402317322258 · Cited by 51
Metadata
- Authors
- Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Nature Genetics
- Published
- 2001-05
- Volume
- 28
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2141354154
- Cited by
- 1,202
- References
- 21
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 19 · 2023: 24 · 2022: 26 · 2021: 38 · 2020: 35 · 2019: 36 · 2018: 39 · 2017: 41 · 2016: 33 · 2015: 40 · 2014: 56 · 2013: 48 · 2012: 64
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ey011142-05)
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY 11142, R01EY013132, R01EY011123, EY-11123, EY 13132)
- National Institute of Neurological Disorders and Stroke (NS36202)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, Leber congenital amaurosis, RPE65, retinal pigment epithelium, photoreceptors, recombinant adeno-associated virus, childhood blindness, vision restoration, inherited retinal degeneration, large animal model
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Disease Models, Animal, Dog Diseases, Dogs, Eye Proteins, Proteins, Genetic Therapy, Optic Atrophies, Hereditary, cis-trans-Isomerases, Animals, Genetically Modified
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.